Citius Oncology reports 86% overall response rate for LYMPHIR in DLBCL trial.

Citius Oncology reports positive topline data from an investigator-initiated Phase 1 trial evaluating LYMPHIR, an immunotherapy for high-risk relapsed or refractory diffuse large B-cell lymphoma. The trial achieved an overall response rate of 86%, including 57% complete response and 29% partial response. LYMPHIR was well-tolerated with no dose-limiting toxicities observed. The trial was conducted by Dr. Veronika Bachanova at the University of Minnesota and City of Hope.